Literature DB >> 17935516

T-cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking.

T N Brooklyn1, A M Williams, M G S Dunnill, C S Probert.   

Abstract

BACKGROUND: The cause of pyoderma gangrenosum (PG) is unknown, but it is likely to be an immune-mediated disease because it is often associated with conditions such as inflammatory bowel disease and rheumatoid arthritis. T cells play an important role in these conditions and have been implicated in the pathogenesis of other skin diseases such as psoriasis.
OBJECTIVES: We examined the T-cell receptor repertoire in PG in order to test the hypothesis that if the T cells were responding to antigen, there would be expanded T-cell clones in the skin and the circulation of these patients. PATIENTS AND METHODS: We studied five patients with PG and examined the T-cell receptor repertoire in cells taken from the peripheral blood and from biopsies of the ulcers, using complementarity determining region 3 spectratyping.
RESULTS: We were able to demonstrate expanded clones in the peripheral blood lymphocyte population of each patient. Clonal expansions within the skin were found in four of the five patients. Most significantly, expanded clones that were shared between the blood and the skin were revealed in four of the five patients.
CONCLUSIONS: These findings imply that T cells play an integral role in the development of PG and suggest that T cells are trafficking to the skin under the influence of an antigenic stimulus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17935516     DOI: 10.1111/j.1365-2133.2007.08211.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  16 in total

1.  Pyostomatitis vegetans: cellular immune profile and expression of IL-6, IL-8 and TNF-alpha.

Authors:  Giuseppe Ficarra; Gianna Baroni; Daniela Massi
Journal:  Head Neck Pathol       Date:  2009-11-14

Review 2.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

Review 3.  Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases.

Authors:  Klaus Eisendle; Tobias Thuile; Jenny Deluca; Maria Pichler
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-04-28       Impact factor: 4.730

4.  Refractory skin lesion, hypertension, and acute kidney injury in a young boy: Answers.

Authors:  Valeriya M Feygina; Thomas F Hahn; Dianne G Muchant
Journal:  Pediatr Nephrol       Date:  2017-01-18       Impact factor: 3.714

Review 5.  [Pyoderma gangrenosum].

Authors:  K Herberger
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

6.  Pyoderma gangrenosum - a guide to diagnosis and management .

Authors:  Christina George; Florence Deroide; Malcolm Rustin
Journal:  Clin Med (Lond)       Date:  2019-05       Impact factor: 2.659

Review 7.  The etiology of paraneoplastic autoimmunity.

Authors:  Emanual Maverakis; Heidi Goodarzi; Lisa N Wehrli; Yoko Ono; Miki Shirakawa Garcia
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

8.  T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum.

Authors:  E Antiga; R Maglie; W Volpi; B Bianchi; E Berti; A V Marzano; M Caproni
Journal:  Clin Exp Immunol       Date:  2017-06-23       Impact factor: 4.330

Review 9.  Effective Strategies for the Management of Pyoderma Gangrenosum.

Authors:  Heidi Goodarzi; Raja K Sivamani; Miki Shirakawa Garcia; Lisa N Wehrli; Hilary Craven; Yoko Ono; Emanual Maverakis
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-10       Impact factor: 4.730

10.  [Psoriasis vulgaris as a trigger for a superficial multilocular pyoderma gangrenosum?].

Authors:  J Klode; A Körber; J Dissemond
Journal:  Hautarzt       Date:  2009-07       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.